Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Switzerland

Research and Innovation Action · Running

PRISMAP+ PRISMAP+ - Furthering the European Medical Radionuclide Programme

Coordinator
Organisation Europeenne Pour La Recherche Nucleaire, Switzerland
Runs
1 May 2026 to 30 April 2029
Status
Running
EU funding
€5.0m
Total cost
€5.0m
Partners
24 organisations in 14 countries
Type
Research and Innovation Action
Grant agreement
101287718

What the project is doing

In the project's own words, from its summary on CORDIS.

PRISMAP + - furthering the European Medical Radionuclide Programme, federates a consortium of 23 beneficiary or associate institutes. Nuclear medicine and research with novel radiopharmaceuticals is fast evolving with the 1st blockbuster treatment radiopharmaceutical Pluvicto® on the market last year. Based on recommendations from the Council of Europe to consolidate the European Radioisotope Valley Initiative programme and associated R&D for medical radionuclides, and therefore to extend the successful PRISMAP programme, PRISMAP + is submitted to this call to coordinate the access for biomedical researchers in Europe to a consortium of leading facilities.

It extends the supply chain in geographical and scope from the maturing PRISMAP consortium, including intense neutron sources, proton and alpha accelerators, mass separation, including 2 new operating accelerators, and hosting researchers in our biomedical hubs. Planned for 2026-2029, the access platform radionuclides.eu will display relevant evolving information, manage the access in the project selection and publish relevant information as projects outcomes and dissemination become necessary.

Accesses to services will furthermore be provided in our biomedical hubs, extended to larger geographical reach in Norway and Greece.

Who is involved

OrganisationCityCountryRole
Organisation Europeenne Pour La Recherche NucleaireGeneve 23SwitzerlandCoordinator
Eanm Forschungs GmbHWienAustriaParticipant
Medizinische Universitat InnsbruckInnsbruckAustriaParticipant
Jrc -Joint Research Centre- European CommissionBruxelles / BrusselBelgiumAssociatedpartner
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Studiecentrum Voor Kernenergie / Centre D'etude De L'energie NucleaireBruxelles / BrusselBelgiumParticipant
Universiteit GentGentBelgiumParticipant
Centre Hospitalier Universitaire VaudoisLausanneSwitzerlandParticipant
Paul Scherrer InstitutVilligen PsiSwitzerlandParticipant
Universite De GeneveGeneveSwitzerlandParticipant
Helmholtz-Zentrum Dresden-Rossendorf eVDresdenGermanyParticipant
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Bioemission Technology Solutions SAGerakas (Athina)GreeceParticipant
Groupement Interet Public ArronaxSaint HerblainFranceParticipant
Institut Max Von Laue - Paul LangevinGrenobleFranceParticipant
Istituto Nazionale Di Fisica NucleareFrascatiItalyParticipant
Latvijas UniversitateRigaLatviaAssociatedpartner
Universitetet I OsloOsloNorwayAssociatedpartner
Narodowe Centrum Badan JadrowychOtwockPolandParticipant
Ist-Id Associacao Do Instituto Superior Tecnico Para a Investigacao E O DesenvolvimentoLisboaPortugalParticipant
Institutul National De Cercetare-Dezvoltare Pentru Fizica Si Inginerie Nucleara-Horia HulubeiMagureleRomaniaParticipant
Npl Management LimitedMiddlesexUnited KingdomParticipant
The University of ManchesterManchesterUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI